Synairgen CEO on funding phase 2 trial for SNG001 Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the companys recent fundraising efforts to support a…
AIM movers: Tiger technology move and Synairgen fundraising Tiger Royalties and Investments (LON: TIR) is changing strategy to become a technology incubator. It is acquiring Bixby Technology Inc,…
Synairgen backer ready to pump £18-£19 million into phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the...…
Synairgen making substantial progress towards phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made substantial progress preparing for a phase II trial of its lead asset,…
Synairgen appoints inhaled drug development expert as chairman Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next months annual shareholder meeting, to be replaced by Mark…
Synairgen making plans for phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe…
Synairgen CEO lays out plans for 2023 and beyond Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…